These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32448094)

  • 1. Computational modeling of cyclic peptide inhibitor-MDM2/MDMX binding through global docking and Gaussian accelerated molecular dynamics simulations.
    Wang YT; Cheng TL
    J Biomol Struct Dyn; 2021 Jul; 39(11):4005-4014. PubMed ID: 32448094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revealing binding selectivity of ligands toward murine double minute 2 and murine double minute X based on molecular dynamics simulations and binding free energy calculations.
    Shi S; Sui K; Liu W; Lei Y; Zhang S; Zhang Q
    J Biomol Struct Dyn; 2020 Oct; 38(17):5081-5094. PubMed ID: 31755361
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: a Brownian dynamics study.
    ElSawy KM; Verma CS; Joseph TL; Lane DP; Twarock R; Caves LS
    Cell Cycle; 2013 Feb; 12(3):394-404. PubMed ID: 23324352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclic Peptide Inhibitors of the Tsg101 UEV Protein Interactions Refined through Global Docking and Gaussian Accelerated Molecular Dynamics Simulations.
    Lin WW; Wang YJ; Ko CW; Cheng TL; Wang YT
    Polymers (Basel); 2020 Sep; 12(10):. PubMed ID: 32998394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
    Pazgier M; Liu M; Zou G; Yuan W; Li C; Li C; Li J; Monbo J; Zella D; Tarasov SG; Lu W
    Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4665-70. PubMed ID: 19255450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational studies of difference in binding modes of peptide and non-peptide inhibitors to MDM2/MDMX based on molecular dynamics simulations.
    Chen J; Zhang D; Zhang Y; Li G
    Int J Mol Sci; 2012; 13(2):2176-2195. PubMed ID: 22408446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designing dual inhibitors of Mdm2/MdmX: Unexpected coupling of water with gatekeeper Y100/99.
    Lee XA; Verma C; Sim AYL
    Proteins; 2017 Aug; 85(8):1493-1506. PubMed ID: 28425639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stochastic modeling and simulation of the p53-MDM2/MDMX loop.
    Cai X; Yuan ZM
    J Comput Biol; 2009 Jul; 16(7):917-33. PubMed ID: 19580521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions.
    Barakat K; Mane J; Friesen D; Tuszynski J
    J Mol Graph Model; 2010 Feb; 28(6):555-68. PubMed ID: 20056466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient p53 activation and apoptosis by simultaneous disruption of binding to MDM2 and MDMX.
    Hu B; Gilkes DM; Chen J
    Cancer Res; 2007 Sep; 67(18):8810-7. PubMed ID: 17875722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probing Origin of Binding Difference of inhibitors to MDM2 and MDMX by Polarizable Molecular Dynamics Simulation and QM/MM-GBSA Calculation.
    Chen J; Wang J; Zhang Q; Chen K; Zhu W
    Sci Rep; 2015 Nov; 5():17421. PubMed ID: 26616018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular modeling and molecular dynamics simulation studies on pyrrolopyrimidine-based α-helix mimetic as dual inhibitors of MDM2 and MDMX.
    Lu SY; Jiang YJ; Zou JW; Wu TX
    J Mol Graph Model; 2011 Sep; 30():167-78. PubMed ID: 21820342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular basis for the inhibition of p53 by Mdmx.
    Popowicz GM; Czarna A; Rothweiler U; Szwagierczak A; Krajewski M; Weber L; Holak TA
    Cell Cycle; 2007 Oct; 6(19):2386-92. PubMed ID: 17938582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leveraging the multivalent p53 peptide-MdmX interaction to guide the improvement of small molecule inhibitors.
    Cheng X; Chen R; Zhou T; Zhang B; Li Z; Gao M; Huang Y; Liu H; Su Z
    Nat Commun; 2022 Feb; 13(1):1087. PubMed ID: 35228542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inferring Leading Interactions in the p53/Mdm2/Mdmx Circuit through Live-Cell Imaging and Modeling.
    Heltberg ML; Chen SH; Jiménez A; Jambhekar A; Jensen MH; Lahav G
    Cell Syst; 2019 Dec; 9(6):548-558.e5. PubMed ID: 31812692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based discovery of novel α-aminoketone derivatives as dual p53-MDM2/MDMX inhibitors for the treatment of cancer.
    Luo HJ; Si DJ; Sun XJ; Wang MY; Yang YB; Wang B; Wen HM; Li W; Liu J
    Eur J Med Chem; 2023 Apr; 252():115282. PubMed ID: 36989812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elaboration of Non-naturally Occurring Helical Tripeptides as p53-MDM2/MDMX Interaction Inhibitors.
    Su A; Tabata Y; Aoki K; Sada A; Ohki R; Nagatoishi S; Tsumoto K; Wang S; Otani Y; Ohwada T
    Chem Pharm Bull (Tokyo); 2021 Jul; 69(7):681-692. PubMed ID: 33952867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
    Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
    Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential binding of p53 and nutlin to MDM2 and MDMX: computational studies.
    Joseph TL; Madhumalar A; Brown CJ; Lane DP; Verma CS
    Cell Cycle; 2010 Mar; 9(6):1167-81. PubMed ID: 20190571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx.
    Czarna A; Popowicz GM; Pecak A; Wolf S; Dubin G; Holak TA
    Cell Cycle; 2009 Apr; 8(8):1176-84. PubMed ID: 19305137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.